ISFP Newsletter

FERTILITY-SPARING SURGERY FOR OVARIAN CANCER AND BORDERLINE TUMORS

Kenny A. Rodriguez-Wallberg MD, PhD (1,2) and Gry Johansen MD (1)

1 - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
2- Department of Reproductive Medicine, Division of Gynecology and Reproduction, Karolinska University Hospital, Stockholm, Sweden

Laboratory Aspects of Establishing a Fertility Preservation Service

Dr. Debra Gook
 

Head of Cryopreservation Services
Royal Women’s Hospital, Melbourne, Australia

Summary of the ISFP congress, New York, 14–16 November, 2019

Dolmans Marie-Madeleine & Hossay Camille & Cacciottola Luciana & Schattman Glenn

Do we need a different nomenclature for ‘oncofertility’?

Could AMH treatment have a role in fertility preservation?

Fertility preservation in patients with Borderline Ovarian Tumors

Ovarian endometriosis and fertility preservation

Anti-Müllerian hormone (AMH) and its multiple purposes in fertility preservation

Fertility preservation in young Leukemia patients

Dr. Shapira Moran, Dr. Ra'anani Hila, Mrs. Sanaz Derech Chaim, Prof. Dror Meirow

Fertility preservation for women with breast cancer

Kenny A. Rodriguez-Wallberg MD, PhD

Oncofertility - the Oncologist point of view

Giovanni Codacci-Pisanelli MD, PhD

Summary of the 3rd Annual Conference of the Fertility Preservation

 Society of India - Fertiprotect, August 2016, Bengaluru, India.

Fertility Consideration in BRCA Mutation Carriers

Dr. Peer Gil, Shapira Moran, Dr. Ra'anani Hila

Young Scientist Congress in Brussels & Update on Fertility Preservation For Girls and Young Women With Cancer

Professor Hamish Wallace

Possible malignant cell contamination in transplanted ovarian tissue Professor Claus Yding Andersen

Transplantation of ovarian tissue in cured cancer patients: is there a risk? Dolmans Marie-Madeleine, MD, PhD.